Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Dana-Farber Cancer Institute
Biotech
Dana-Farber oncologist Anthony Letai tapped to direct NCI
Work led by Letai resulted in the development of AbbVie and Roche’s Venclexta (venetoclax), which was first approved by the FDA in 2016 for leukemia.
Darren Incorvaia
Sep 30, 2025 5:50am
Cancer vaccine prevents kidney cancer comeback in small trial
Feb 6, 2025 3:00pm
BMS vet answers Foghorn’s call for CBO—Chutes & Ladders
Sep 6, 2024 8:30am
Chemo drug boosts Daiichi Sankyo ADC in prostate cancer models
Nov 16, 2023 7:35am
Precede's liquid biopsy uncovers transcriptional cancer markers
Oct 23, 2023 2:50pm
Dana-Farber's Precede debuts with $57M for blood biopsy tests
Oct 6, 2023 10:15am
